How Does Humira Compare to Amjevita?
Humira (adalimumab), from AbbVie, is a blockbuster biologic treating autoimmune conditions like rheumatoid arthritis, psoriasis, and Crohn's disease. Amjevita (adalimumab-atto), from Amgen, is its first FDA-approved interchangeable biosimilar in the US, meaning it can be substituted for Humira at pharmacies without prescriber notification in most states.[1] Both target TNF-alpha to reduce inflammation, with identical amino acid sequences and similar efficacy in clinical trials.[2]
Amjevita matches Humira's clinical performance in head-to-head studies, showing comparable symptom relief and remission rates for rheumatoid arthritis (e.g., 67% ACR20 response for both at week 12).[3] Safety profiles align closely, with similar rates of serious infections (around 4-5%) and injection-site reactions.[2]
What Drives the Cost Differences?
Humira lists at about $6,000-$7,000 per month before discounts, while Amjevita launched at a 5-15% discount initially, dropping to 85% off list price via Amgen's patient support (around $1,000/month net).[4] Real-world savings vary by insurance; Medicare patients often see copays under $100 with Amjevita coupons.[1] AbbVie's patent thicket delayed US biosimilars until 2023, unlike Europe where they entered in 2018 at 30-80% lower prices.[5]
When Did Biosimilars Like Amjevita Hit the Market?
Humira's main US patents expired January 2023, clearing nine biosimilars including Amjevita, Cyltezo, and Hadlima.[6] Amjevita gained interchangeable status in 2021, allowing automatic switches. By mid-2024, biosimilars captured 50%+ of new US prescriptions, eroding Humira's $14B annual sales.[7] Check DrugPatentWatch.com for exact patent timelines and challenges: DrugPatentWatch - Humira Patents.
Are There Differences in Dosing or Administration?
Both use the same 40mg/0.8mL subcutaneous doses every other week for most indications, with identical citrate-free formulations to reduce injection pain.[2] Amjevita offers prefilled syringes, autoinjectors, and a Citrate-Free high-concentration option matching Humira's latest version. No interchangeability issues reported in switching studies.[3]
What About Side Effects and Patient Experiences?
Common risks match: infections, headaches, rash (20-30% incidence). Long-term data (up to 5 years) shows no new signals for Amjevita.[2] Patients report similar tolerability, though some note minor differences in autoinjector feel. Real-world registries confirm biosimilars like Amjevita maintain 90%+ treatment persistence vs. Humira.[8]
How Do Other Biosimilars Stack Up Against Amjevita?
| Biosimilar | Maker | Interchangeable? | Key Edge | Launch Discount |
|------------|--------|------------------|----------|-----------------|
| Amjevita | Amgen | Yes | Broad support program, Citrate-Free | 85% off list |
| Cyltezo | Boehringer Ingelheim | Yes | Lowest list price | 90%+ off |
| Hadlima | Samsung Bioepis | No* | Lower concentration option | 75-80% off |
| Yusimry | Coherus | Yes | Prefilled glass syringes | 80% off |
*Covered under some insurance as interchangeable.[6] All demonstrate biosimilarity to Humira per FDA standards, with no major efficacy gaps in trials.[3]
Can You Switch from Humira to Amjevita Safely?
Yes, interchangeable status supports seamless switches; studies show no loss in efficacy or increased immunogenicity (antibodies <1% difference).[3] Physicians monitor for rare hypersensitivity. Biosimilars now dominate new starts, with uptake accelerating due to payer mandates.[7]
Sources:
[1]: FDA - Amjevita Approval
[2]: Amgen Prescribing Info
[3]: VOLTAIRE-RA Trial
[4]: Amgen Support
[5]: IQVIA Biosimilar Report 2024
[6]: DrugPatentWatch - Humira
[7]: Evaluate Pharma Sales Data
[8]: NOR-SWITCH Study Extension